Actively Recruiting
Replication of the Heads Up Atopic Dermatitis Trial With Registry Data
Led by Technische Universität Dresden · Updated on 2025-08-21
240
Participants Needed
1
Research Sites
230 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal is the replication of the primary outcome (EASI 75 at week 16) of the Heads Up trial (Blauvelt, A, Teixeira, H, Simpson, E et al (2021) doi:10.1001/jamadermatol.2021.3023) and the evaluation of the patient reported outcomes (POEM, DLQI and RECAP) in a head-to-head comparison of upadacitinib versus dupilumab treatment in moderate-to-severe atopic dermatitis (AD).
CONDITIONS
Official Title
Replication of the Heads Up Atopic Dermatitis Trial With Registry Data
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Chronic atopic dermatitis with symptoms starting at least 3 years before baseline
- Meets UK working party criteria for atopic dermatitis
- Eczema Area and Severity Index (EASI) score of 16 or higher
- At least 10% body surface area affected by atopic dermatitis at baseline (therapy start) visit
You will not qualify if you...
- Any contraindications to upadacitinib or dupilumab as specified in their labeling
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Center for Evidence Based Health Care
Dresden, Saxony, Germany, 01307
Actively Recruiting
Research Team
T
Thomas Birkner
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here